Browse News
Filter News
Found 685,406 articles
-
A day after the FDA authorized a COVID-19 booster dose of the Pfizer-BioNTech vaccine, a U.S. Centers for Disease Control and Prevention advisory committee voted in support.
-
There are roughly 750 sales representatives for Amarin at present, which the company intends to whittle down to 300 as it adopts a more digital approach to marketing.
-
September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead.
-
Aside from the fraud trial of Theranos founder Elizabeth Holmes, other court-related cases are taking place, including between Takeda and AbbVie over cancer drug, Lupron.
-
Esker Therapeutics tapped Martin Babler to helm the company after founding CEO June Lee has stepped away to pursue other opportunities.
-
On Friday morning, Capricor announced positive final data from the HOPE-2 trial of its drug candidate, CAP-1002, indicating a slowing of disease progression in this population.
-
Study: Adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TILs) is more effective in patients who have not been treated with checkpoint inhibitors than in those who have undergone one or more therapies.
-
The National Kidney Foundation and the American Society of Nephrology recommend removing race from the equation in the assessment of kidney disease.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
-
BioSpace Movers & Shakers, Sept. 24
9/24/2021
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Researchers from the Max Planck Institute for Heart and Lung Research reportedly achieved positive results after returning adult cardiomyocytes to their fetal-like state in mouse models.
-
CPhI Report predicts record EBITDAs for CDMOs in 2022
9/24/2021
Part one of the 2021 CPhI Annual Report predicts an increasingly bullish outlook for CDMOs in the next 2-3 years, with macro factors significantly driving up demand and prices for mergers and acquisitions.
-
Kizoo Portfolio Company Underdog Closes $10M Financing Round
9/24/2021
Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
-
Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
9/24/2021
Jasper Therapeutics, Inc. today announced the completion of its business combination with Amplitude Healthcare Acquisition Corporation
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9/24/2021
Mirati Therapeutics, Inc. today announced that in connection with the hiring, announced on September 20, 2021, of David Meek as Chief Executive Officer, Mr. Meek received an inducement award to purchase up to 150,300 shares of common stock.
-
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
9/24/2021
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon
-
Scipher Medicine Welcomes Sam Davis as General Counsel
9/24/2021
Scipher Medicine today announced the appointment of Sam A. Davis, JD, as General Counsel.
-
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
9/24/2021
Research aims to confirm evidence of the expression of human endogenous retrovirus W envelope protein (HERV-W ENV or W-ENV) in long-haul COVID patients, and identify affected patients who may benefit from a treatment with GeNeuro’s temelimab.
-
Instadose Pharma Corp Merger
9/24/2021
Instadose Pharma Corp. today announced that it has entered into a plan of arrangement to acquire all the issued and outstanding shares of Instadose Pharma Corp., a corporation organized under the laws of Canada.